DNAprint Genomics (DNAG)

[manysevens]

Frud please ... you make it sound as though the idea for a new anemia drug was just concieved of that morning. lol. Don't you think they had do a little somn' somn' just to get to that point?

And Frud ... I'm a little investor ... and an honest one ... I do not and would not even consider intentionally distorting any info for the purpose of attracting new investors or for any other reason. lol ... that was a good one. Give me a break.

Fact is .. the development of drugs has always been on the table for DNAPrint. Period.

I am still anxious to see a link that provides info on the whopping O/S that you claim exists.

Some links ...

Going back to the year 2000 ...

"According to the Barron's article, Dnaprint is in the late stages of forming strategic alliances with major companies."
http://lists.w3.org/Archives/Public/site-comments/2000Sep/att-0056/00-part

***

"Since its inception, DNAPrint genomics successfully has leveraged its broad-based expertise in genomics into three business segments -- ancestry for the consumer market, forensics technology for law enforcement and pharmacogenomics -- personalized medicine based on a patient's DNA," stated Company President and Chief Executive Officer Richard Gabriel.

So it would seem to me that DNAG has been involved in the research and development of it's drugs AND tests for over five years. Ageed?

DNAPrint genomics, Inc. ( http://www.dnaprint.com/ ) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company's first theranostic product (drug/test combination) is PT- 401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre- clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response.